Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

• Published in: Diabetes care Vol. 36; no. 10; pp. 2923 - 2930
• Main Authors: Cariou, Bertrand, Hanf, Rémy, Lambert-Porcheron, Stéphanie, Zaïr, Yassine, Sauvinet, Valérie, Noël, Benoit, Flet, Laurent, Vidal, Hubert, Staels, Bart, Laville, Martine
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01.10.2013
• Subjects: Adult; Biological and medical sciences; Chalcones - adverse effects; Chalcones - therapeutic use; Complications and side effects; Cross-Over Studies; Diabetes. Impaired glucose tolerance; Dosage and administration; Drug therapy; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Female; Genetic aspects; Humans; Hypoglycemic agents; Insulin Resistance - physiology; Lipoproteins - blood; Liver - drug effects; Liver - enzymology; Male; Medical sciences; Metabolic diseases; Middle Aged; Muscle, Skeletal - drug effects; Muscle, Skeletal - metabolism; Obesity; Obesity - blood; Obesity - drug therapy; Obesity - metabolism; Original Research; PPAR alpha - agonists; PPAR delta - agonists; Propionates - adverse effects; Propionates - therapeutic use; Type 2 diabetes; France; Human; Obesity; Pancreatic hormone; Agonist; Nutrition; Digestive system; Insulin sensitivity; Liver; Nutrition disorder; Metabolic diseases; Insulin; PPAR-α receptor; Improvement; Endocrinology; Nutritional status

The development of new insulin sensitizers is an unmet need for the treatment of type 2 diabetes. We investigated the effect of GFT505, a dual peroxisome proliferator-activated receptor (PPAR)-α/δ agonist, on peripheral and hepatic insulin sensitivity. Twenty-two abdominally obese insulin-resistant...